The target hemoglobin in patients with chronic kidney disease.
Singh
Ajay K
AK
Brigham and Women's Hospital, Boston, and Harvard Medical School, MA, USA.
D000740:Anemia / Q000097:blood / Q000209:etiology / Q000628:therapy; D015982:Bias; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control; D015986:Confounding Factors, Epidemiologic; D016903:Drug Monitoring; D004921:Erythropoietin / Q000494:pharmacology / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006454:Hemoglobins / Q000187:drug effects*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000523:psychology; D009017:Morbidity; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D016896:Treatment Outcome
D006454:Hemoglobins; D004921:Erythropoietin